Role of Nutritional Therapy in Alcoholic Hepatitis — Dr. Chetan Kalal at Juhu IMA 2026

Dr. Chetan Kalal delivered the invited lecture “Role of Nutritional Therapy in Alcoholic Hepatitis” at the Juhu IMA (Indian Medical Association) 2026 meeting — one of the most contested topics in hepatology practice, where nutritional support is simultaneously the most accessible intervention and the most consistently under-utilised one.

Why Nutrition in Alcoholic Hepatitis Is Not a Soft Topic

Alcoholic hepatitis (AH) — now increasingly termed alcohol-associated hepatitis (AAH) — carries a 28-day mortality of 20–50% in severe disease (MELD >20, discriminant function ≥32). Corticosteroids remain the only pharmacological intervention with proven mortality benefit in selected patients, and even that benefit is modest and short-lived beyond 28 days. In this context, nutritional therapy is not adjunctive — it is potentially the highest-impact intervention available for the majority of patients.

Malnutrition in alcoholic hepatitis is almost universal. Studies consistently show that 80–100% of hospitalised severe AH patients have protein-calorie malnutrition, with sarcopenia (loss of skeletal muscle mass) present in the majority. Sarcopenia in AH is not an incidental finding — it is independently associated with mortality, hepatic encephalopathy risk, infection susceptibility, and failure to respond to corticosteroids.

In severe alcoholic hepatitis, the catabolic state is driven by systemic inflammation, elevated TNF-α and IL-6, alcohol-induced mitochondrial dysfunction, and inadequate spontaneous oral intake. A patient admitted with severe AH and sarcopenia is losing muscle mass at a rate that will not be rescued by corticosteroids alone. Nutritional therapy — delivered adequately and early — is the intervention that addresses the catabolic substrate.

Nutritional Assessment in Alcoholic Hepatitis

Nutritional assessment in cirrhotic and AH patients requires tools adapted to the liver disease context — standard BMI is unreliable in the presence of ascites and oedema. Recommended assessment tools:

• Royal Free Hospital Global Assessment (RFH-GA) — validated specifically in cirrhosis and AH. Incorporates BMI, mid-arm muscle circumference (MAMC), and dietary intake. Score 1–2: well-nourished; 3: malnourished.
• Mid-arm muscle circumference (MAMC) — unaffected by fluid retention; reliable proxy for skeletal muscle mass in the presence of ascites
• Handgrip strength (HGS) — rapid, non-invasive, validated sarcopenia marker. HGS <30kg (men) and <20kg (women) indicates sarcopenia. Independently predicts 6-month mortality in cirrhosis.
• BIA (bioelectrical impedance analysis) — phase angle on BIA is a reliable muscle mass marker in decompensated cirrhosis. Phase angle <4.9° in cirrhotic patients predicts poor outcomes.
• CT-based psoas muscle index — if CT abdomen available (e.g. for ascites evaluation), L3 skeletal muscle index is the reference standard for sarcopenia diagnosis.

Nutritional Requirements in Severe Alcoholic Hepatitis

Based on EASL CPG on Nutrition in CLD (2019) and ESPEN guidelines:

• Energy: 35–40 kcal/kg/day (use dry weight or estimated dry weight adjusted for ascites)
• Protein: 1.2–1.5 g/kg/day — higher than historic recommendations, which had inappropriately restricted protein in encephalopathy (now discredited). Protein restriction worsens sarcopenia and impairs hepatic regeneration; it should not be practised except in the most refractory encephalopathy.
• Micronutrients: Thiamine (B1) — IV replacement before any glucose administration (to prevent Wernicke’s encephalopathy). Folate, B6, B12, zinc, magnesium — all commonly deficient.
• Frequency: Late evening snack (LES) — 50g complex carbohydrate before sleep significantly reduces overnight gluconeogenesis from muscle catabolism. Simple, effective, and consistently underused.

Route of Nutritional Support

The preferred route depends on the patient’s functional status and encephalopathy grade:

• Oral nutrition first — if the patient is eating, optimise oral intake with high-protein supplements (2 kcal/ml, 20g protein/200ml drinks). Target 5–6 small meals including the LES.
• Nasogastric tube feeding — if oral intake inadequate (<70% of target for >2 days). Nasogastric feeding is safe in AH including in the presence of varices (NICE CG100; AASLD 2019). Fear of variceal bleeding from NG tubes should not prevent enteral nutrition — evidence does not support this concern.
• Parenteral nutrition (PN) — only if enteral route is genuinely unavailable (paralytic ileus, severe vomiting unresponsive to antiemetics, intestinal failure). PN is less effective than enteral feeding for gut mucosal integrity and is associated with higher infection risk. It is not the default for “difficult” AH patients — NG tube insertion should be attempted first.

Evidence Base — Nutritional Therapy in AH

The landmark trial establishing nutritional therapy equivalence to corticosteroids in AH was the Mendenhall et al. VA Cooperative Study — intensive nutritional therapy produced 30-day survival outcomes comparable to corticosteroids in a subset of patients. More recent data:

• NUTRIHEP trial — NG tube feeding in severe AH: patients receiving ≥21.5 kcal/kg/day had significantly lower 6-month mortality than those receiving less. Every 10 kcal/kg/day increase in caloric intake was associated with reduced mortality risk.
• STOPAH trial (NEJM 2015) — the largest AH RCT (n=1053) showed prednisolone improved 28-day survival but this benefit was lost at 90 days and 1 year. Nutritional status was a major confounder — better-nourished patients had better outcomes regardless of steroid allocation.
• Meta-analyses — nutritional support in AH is associated with reduced 28-day mortality, reduced infection rates, and reduced hepatic encephalopathy. Effect size is comparable to or greater than corticosteroids in some analyses, particularly at 90 days and 1 year.

Branched-Chain Amino Acids (BCAAs) in AH

BCAAs (leucine, isoleucine, valine) deserve specific mention. In alcoholic hepatitis with hepatic encephalopathy, aromatic amino acids (AAAs) are elevated (impaired hepatic clearance) while BCAAs are depleted (consumed by peripheral muscles). This BCAA:AAA imbalance (Fischer ratio) contributes to encephalopathy via false neurotransmitter synthesis. BCAA supplementation:

• Corrects the Fischer ratio
• Provides anabolic substrate for muscle (sparing muscle catabolism)
• Reduces encephalopathy episodes (data primarily from cirrhosis cohorts, extrapolated to AH)
• Improves Child-Pugh score at 6 months in supplemented patients (Japanese RCTs)

BCAA supplements are available in granule, liquid, and IV forms. They are particularly indicated in patients with recurrent HE, significant sarcopenia, or intolerance to standard protein sources.

Zinc and Micronutrient Repletion

Zinc deficiency is ubiquitous in AH — alcohol impairs zinc absorption and increases renal zinc excretion. Zinc is essential for alcohol dehydrogenase function, gut barrier integrity (tight junctions), and immune function. Zinc supplementation (50mg elemental zinc/day for 3–6 months) improves gut permeability, reduces endotoxaemia, and has shown histological benefit in MASH (which shares metabolic pathways). Routine zinc repletion in AH is recommended in AASLD and EASL guidelines.

Practical Protocol — Nutritional Management of Severe AH

1. Admission bloods: albumin, prealbumin, zinc, magnesium, phosphate, thiamine (clinical assessment if assay unavailable)
2. Thiamine 100–200mg IV immediately (before glucose)
3. Nutritional assessment: RFH-GA, HGS, MAMC within 24 hours
4. Dietitian referral same day — calculate dry weight caloric and protein targets
5. Start oral high-protein supplementation (if tolerating oral intake)
6. If oral intake <70% of target at 48 hours: insert NG tube, start enteral feed at 20ml/hr, titrate to target over 24–48 hours
7. Late evening snack: 50g complex carbohydrate (e.g. 2 Ensure sachets, banana + milk) before sleep — every night
8. Zinc 50mg elemental/day, B-complex supplementation, folate 5mg/day
9. Monitor for refeeding syndrome: check phosphate, magnesium, potassium at 48 and 96 hours after refeeding initiation

Dr. Chetan Kalal is Associate Director, Hepatology & Transplant Medicine, Gleneagles Hospital Mumbai. DM (Hepatology), MRCP (UK). Maharashtra’s first DM Hepatologist. Research interest: nutrition and sarcopenia in liver disease. Invited Faculty at Juhu IMA 2026, IMPA 2026, Obesity Masterclass 2026, LTSICON 2026, and Organising Secretary of Grand Rounds in Hepatology 2026 (INASL Mid-Term). Referrals: drchetankalal.com/book.

Frequently Asked Questions

Can alcoholic hepatitis be treated without steroids?

Yes — for mild-to-moderate AH (discriminant function <32, MELD <20), corticosteroids are not indicated. Nutritional therapy, abstinence support, and management of complications is the standard of care. For severe AH, corticosteroids (prednisolone 40mg/day × 28 days) are first-line — but must be combined with nutritional support, not used instead of it. Patients who do not respond to steroids at day 7 (Lille score >0.45) should have steroids stopped — nutritional support continues regardless.

Is it safe to feed a patient with alcoholic hepatitis through a feeding tube?

Yes. NG tube feeding is safe in AH, including in patients with oesophageal varices. Properly placed NG tubes do not significantly increase variceal bleed risk. The risk of malnutrition and its consequences — sarcopenia, encephalopathy, infection — far outweighs the marginal (unproven) theoretical risk of NG tube-related variceal trauma.

Should protein be restricted in alcoholic hepatitis with encephalopathy?

No. This practice — protein restriction in HE — was based on the (incorrect) assumption that dietary protein drives HE. HE in AH and cirrhosis is driven by sarcopenia, infection, constipation, GI bleed, and metabolic disturbance — not by adequate dietary protein. Protein restriction worsens sarcopenia and worsens long-term HE risk. Target 1.2–1.5g/kg/day protein even during episodes of HE, switching to BCAA supplements if standard protein is genuinely not tolerated.

---

Medical disclaimer: This article is for educational purposes and does not constitute personalised clinical advice.